We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Significance of Heterogeneity in Response to Retreatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Cancer Acquiring Secondary Resistance to the Drug.
- Authors
Youngjoo Lee; Hyae Young Kim; Soo-Hyun Lee; Kun Young Lim; Geon Kook Lee; Tak Yun; Ji-Youn Han; Heung Tae Kim; Jin Soo Lee
- Abstract
To elucidate clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), tumor response to second EGFR-TKIs was assessed per patient and per organ in 68 patients. Of 35 cases of progressive disease, 22 (62.8%) showed mixed response. The organ type and prior drug sensitivity at the failure time of first EGFR-TKIs may predict the efficacy of second EGFR-TKIs in organs. Background: In patients with lung cancer acquiring resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), an intrapatient heterogeneity in response to retreatment with EGFR-TKIs remains to be elucidated. Patients and Methods: Records were retrospectively reviewed for 68 patients with advanced non-small-cell lung cancer who received second EGFR-TKIs after systemic progression that followed durable response to the first EGFR-TKIs. All tumor lesions identified on radiologic images before second EGFR-TKIs were categorized into organs. Tumor response to EGFR-TKIs was assessed per patient and per organ. Mixed response (MR) was defined as the coexistence of at least 2 responsive and progressive organs. Results: Tumor lesions were detected in 244 organs. The response rate (RR) and median time to progression (TTP) to second EGFR-TKIs for patients were 26.5% and 11.6 weeks (95% CI, 8.5-14.7 weeks), and the RR and median TTP for organs were 38.8% and 17.3 weeks (95% CI, 14.8-19.8 weeks). Of 35 patients categorized to progressive disease, 22 (62.8%) showed MR. Among organs, the RR was highest for the central nervous system (CNS) and lowest for the liver (CNS vs. others vs. liver: 77.8%, 36.9%, 17.6%; P < .001). Multivariate analysis confirmed the organ type and prior drug sensitivity at the time of stopping first EGFR-TKIs as predictors for the risk of progression to second EGFR-TKIs in organs. Conclusions: Intrapatient heterogeneity in response to second EGFR-TKIs is not a rare event. The organ type and prior drug sensitivity at the failure time of first EGFR-TKIs may predict the efficacy of second EGFR-TKIs in individual organs.
- Publication
Clinical Lung Cancer, 2014, Vol 15, Issue 2, p145
- ISSN
1525-7304
- Publication type
Article
- DOI
10.1016/j.cllc.2013.11.008